TFF Pharmaceuticals Provided An Update From Its Ongoing Phase 2 Trial Of Tacrolimus Inhalation Powder For The Prevention Of Lung Transplant Rejection
$TFFP
Biotechnology: Pharmaceutical Preparations
Health Care
- Patient Enrollment Has Accelerated with Now 10 Patients Enrolled in Phase 2 Trial.
- 6 out of 6 Patients Who Completed the 12-Week Treatment Have Chosen to Remain on TFF TAC by Proceeding to the Safety Extension Phase; 1 patient has been treated for over a year and 3 additional patients have been treated for more than 6 months.
- Variability in Systemic Exposure to Tacrolimus Was Reduced with TFF TAC Which Could Lower Risk of Acute Rejection and Systemic Toxicities.